Ann: ATL1102 Revised Plans accelerate reporting of unblinded data, page-62

It's the road to scientific data, and not the road to commercialization that we wanted.

I think strategic options are on the table, get to a point where there is M&A action with some validated proof.

There has been no changes in organizational structure/design that you would expect for a company headed into P3/pivotal trial.

In my mind MD has run out of lives. You can't go through this many strategic last minute shifts or c*ck ups without falling on your sword. Some would argue this is beyond his control, but it is time.

All of 2022 was promises to align the FDA, but I've seen none of that, which gets me angry on driving value catalysts.

Kiss goodbye to options. Kiss goodbye to PRV.